title: Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins.
abstract: A new molecular entity, PER977 (di-arginine piperazine), is in clinical development as an anticoagulant reversal agent for new oral anticoagulants and heparins. The good laboratory practices (GLP)-compliant studies were conducted to evaluate the toxicity of PER977 and its primary metabolite, 1,4-bis(3-aminopropyl)piperazine (BAP). PER977 and BAP were negative for systemic toxicity in dogs and rats. PER977 was rapidly eliminated from the blood with little to no accumulation. PER977 was negative for genotoxicity and did not alter neurological, respiratory, or cardiovascular function. Maximum tolerated doses for PER977 were 40 (rat) and 35 mg/kg (dog), and greater than 80 mg/kg (rat) for BAP. The no observable adverse effect level (NOAEL) for 14-day intravenous exposure to both rats and dogs was 20 mg/kg/d. For BAP, the NOAELs for 14-day intravenous exposure to rats and dogs were 5 and 20 mg/kg, respectively. Based on these results, a safe and conservative dose level of 19.4 mg/d was used for the PER977 first in human study.
authors.affiliation: Gad Consulting Services, Raleigh, NC, USA dwsullivanjr@gmail.com.
authors.forename: Dexter W
authors.initials: DW
authors.lastname: Sullivan
authors.affiliation: Gad Consulting Services, Raleigh, NC, USA.
authors.forename: Shayne C
authors.initials: SC
authors.lastname: Gad
authors.affiliation: Perosphere Inc, Danbury, CT, USA.
authors.forename: Bryan
authors.initials: B
authors.lastname: Laulicht
authors.affiliation: Perosphere Inc, Danbury, CT, USA.
authors.forename: Sasha
authors.initials: S
authors.lastname: Bakhru
authors.affiliation: Perosphere Inc, Danbury, CT, USA.
authors.forename: Solomon
authors.initials: S
authors.lastname: Steiner
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D004249:DNA Damage; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006494:Heparin Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D010879:Piperazines / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018675:Toxicity Tests
chemical_list: D006494:Heparin Antagonists; D010879:Piperazines; C486841:1,4-bis(3-aminopropyl)piperazine; D001120:Arginine; C000593571:PER977
keywords: BAP; NOAC; PER977; anticoagulant; drug; reversal agent